Varenicline Tartrate is Used for treating dry eye disease symptoms. It was first introduced by Pf Prism Cv in its drug Chantix on May 10, 2006. Another drug containing Varenicline Tartrate is Tyrvaya. 13 different companies have introduced drugs containing Varenicline Tartrate.

Varenicline Tartrate Patents

Given below is the list of patents protecting Varenicline Tartrate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Chantix	US6410550	Aryl fused azapolycyclic compounds	May 10, 2020 (Expired)	Pf Prism Cv
Chantix	US6410550 (Pediatric)	Aryl fused azapolycyclic compounds	Nov 10, 2020 (Expired)	Pf Prism Cv
Chantix	US6890927	Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof	May 06, 2022 (Expired)	Pf Prism Cv
Chantix	US6890927 (Pediatric)	Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof	Nov 06, 2022 (Expired)	Pf Prism Cv
Chantix	US7265119	Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof	Aug 03, 2022 (Expired)	Pf Prism Cv
Chantix	US7265119 (Pediatric)	Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof	Feb 03, 2023 (Expired)	Pf Prism Cv
Tyrvaya	US10456396	Dry eye treatments	Oct 19, 2035	Oyster Point Pharma
Tyrvaya	US11224598	Methods of increasing lacrimal proteins	Oct 19, 2035	Oyster Point Pharma
Tyrvaya	US11903941	Compositions and use of varenicline for treating dry eye	Oct 19, 2035	Oyster Point Pharma
Tyrvaya	US11903942	Compositions and use of varenicline for treating dry eye	Oct 19, 2035	Oyster Point Pharma
Tyrvaya	US11903943	Compositions and use of varenicline for treating dry eye	Oct 19, 2035	Oyster Point Pharma
Tyrvaya	US11911380	Compositions and use of varenicline for treating dry eye	Oct 19, 2035	Oyster Point Pharma
Tyrvaya	US9504644	Methods of increasing tear production	Oct 19, 2035	Oyster Point Pharma
Tyrvaya	US9504645	Pharmaceutical formulations for treating ocular conditions	Oct 19, 2035	Oyster Point Pharma
Tyrvaya	US9532944	Methods of improving ocular discomfort	Oct 19, 2035	Oyster Point Pharma
Tyrvaya	US9597284	Dry eye treatments	Oct 19, 2035	Oyster Point Pharma

Add above patents to watchlist

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Varenicline Tartrate's patents.

Latest Legal Activities on Varenicline Tartrate's Patents

Given below is the list recent legal activities going on the following patents of Varenicline Tartrate.

Event	Date	Patent/Publication
Today's Legal Activities
Payment of Maintenance Fee, 8th Year, Large Entity	25 Jun, 2024	US9532944
Patent eCofC Notification	04 Jun, 2024	US11903942
Email Notification	04 Jun, 2024	US11903942
Recordation of Patent eCertificate of Correction	04 Jun, 2024	US11903942
Mail Patent eCofC Notification	04 Jun, 2024	US11903942
Payment of Maintenance Fee, 8th Year, Large Entity	21 May, 2024	US9504645
Payment of Maintenance Fee, 8th Year, Large Entity	21 May, 2024	US9504644
Post Issue Communication - Certificate of Correction	15 May, 2024	US11903942
Patent eGrant Notification	27 Feb, 2024	US11911380
Mail Patent eGrant Notification	27 Feb, 2024	US11911380

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳